Palbociclib is an oral selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. It is FDA-approved for the treatment of hormone...

Fruquintinib, a US FDA-approved inhibitor for metastatic colorectal cancer  Fruquintinib, marketed under the brand name Fruzaqla, is an...

Tislelizumab: superior efficacy in ESCC Tislelizumab is a recombinant humanized IgG4 kappa monoclonal antibody that targets the...

Ivonescimab - Promising Efficacy in NSCLC Ivonescimab, also known as AK112, is a novel bispecific monoclonal antibody that simultaneously...

Zanubrutinib, marketed as Brukinsa, is a highly selective second-generation Bruton's tyrosine kinase (BTK) inhibitor developed to enhance...